临床试验支援服务市场－全球产业规模、份额、趋势、机会及预测（按服务、申办方、地区及竞争格局划分，2021-2031年）

全球临床试验支援服务市场预计将从 2025 年的 217.6 亿美元成长到 2031 年的 296.8 亿美元，复合年增长率为 5.31%。

这些服务包括专业的行政和营运职能，例如试验地点选择、病患招募、资料管理和法规遵从，製药和生物技术公司将这些职能外包，以确保临床试验的有效进行。推动该市场成长要素是试验通讯协定日益复杂以及缩短药物研发週期的迫切需求，迫使企业依赖外部专业知识来简化营运。大量投资支撑着这一需求，欧洲製药工业协会联合会 (EFPIA) 报告称，2023 年欧洲製药业将在研发方面投资约 524 亿欧元。

阻碍市场成长的一大挑战是招募和留住合格试验参与者的持续困难。病患流失率高以及接触不同族群的后勤障碍常常导致成本高昂的延误和研究週期延长。这些瓶颈造成了严重的效率低下，耗费了服务提供者和申办者的大量资源，有效地限制了整个临床研究生态系统及时交付结果的能力，并延缓了新疗法的推出。

市场驱动因素

生物製药领域研发支出不断成长是推动市场发展的根本动力。将非核心职能策略性外包给专业供应商对于维持财务永续性至关重要。由于面临优化资本配置和降低临床试验失败相关财务风险的压力，药物研发企业越来越依赖外部支援来进行监测、资料管理和监管事务。这一趋势体现在对开发平臺的大量资本投入上，例如，默克公司在其2023年年度报告中披露，其年度研发支出高达305亿美元。这反映了一项强有力的投资策略，该策略将持续满足临床研究生态系统内对营运专业知识的需求。

同时，慢性病和感染疾病的日益普及扩大了临床研究的范围，增加了所需试验的数量和复杂性。疾病负担的快速成长迫使申办方，尤其是在肿瘤学和免疫学领域，启动需要大规模病患招募、研究中心管理和物流协调的大规模研究。根据美国癌症协会发布的《2024年癌症事实与数据》，预计仅在美国就将新增2,001,140例癌症病例，凸显了对新型治疗方法进行严格临床评估的迫切需求。这种医疗需求也体现在市场活动中，美国食品药物管理局（FDA）在2023年核准了55种新型疗法就证明了这一点。如此高的核准数量凸显了顺利完成监管流程所需的广泛支援服务的重要性。

市场挑战

招募和留住合格试验参与者的持续挑战，严重限制了全球临床试验支援服务市场的发展。未能达到患者入组目标会延长整体临床开发週期，迫使支援服务提供者将人力和技术资源投入到正在进行的计划中，且持续时间远超预期。这种积压导致合约研究组织 (CRO) 和专业供应商无力启动新契约，直接限制了收入潜力，并减缓了整体市场周转率。

根据临床研究专业人员协会 (ACRP) 的预测，到 2024 年，36% 的临床研究机构将把病患招募和留存视为影响研究结果的最大营运挑战。由于服务费用通常与特定的入组里程碑挂钩，这些延误会扰乱市场的财务生态系统。因此，无法有效率地招募患者限制了产业的规模化发展能力，即使全球对临床研究的需求不断增长，也有效地阻碍了支持服务的发展。

市场趋势

人工智慧 (AI) 在预测分析和病患招募的应用，正从根本上改变临床试验的运作方式，实现更精准的试验中心选择和资料处理速度的提升。服务供应商正积极部署机器学习演算法，分析电子健康记录，以比传统筛检方法更准确地识别合格的患者群体。这项技术变革直接解决了人工资料处理效率低下的难题，使申办方能够优化通讯协定可行性并有效缩短试验週期。根据皮斯托亚联盟发布的《2025 年未来实验室全球调查》，63% 的生命科学公司将人工智慧视为关键技术投资领域，这标誌着为维持营运竞争力，试验执行策略正发生决定性转变，转向自动化、数据驱动的模式。

分散式和混合式临床试验模式的普及代表着服务提供方式的一次重要变革，它将研究活动从实体机构转移到患者家中，并透过远端医疗和行动医疗支援来实现。这种模式不仅透过减少患者的出行负担来提高患者的参与率，而且还成为满足有关参与者多样性监管要求的主要途径。透过消除地域障碍，支持服务可以有效地涵盖那些通常被排除在传统机构研究之外的代表性不足的人群。塔夫茨药物研发研究中心于2025年1月发布的一项PACT联盟分析发现，分散式试验方法将亚洲患者的参与率从传统试验的14.2%提高到20.9%，这表明该模式在扩大人群覆盖范围和提高数据代表性方面具有显着成效。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球临床试验支援服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依服务项目划分（临床试验中心管理、病患招募管理（病患招募与登记服务、病患保留等）、资料管理、行政人员、伦理审查委员会等）
  • 依赞助商分类（药品/生物药品、医疗设备、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美临床试验支援服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲临床试验支援服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区临床试验支援服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲临床试验支援服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲临床试验支援服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球临床试验支援服务市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Charles River Laboratories International, Inc.
• Wuxi Apptec
• IQVIA Inc
• Syneos Health
• Eurofins Scientific
• Ppd, Inc（Thermo Fisher Scientific Inc.）
• ICON plc
• Laboratory Corporation Of America Holdings
• Parexel International（MA）Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Clinical Trials Support Services Market is projected to expand from USD 21.76 Billion in 2025 to USD 29.68 Billion by 2031, reflecting a CAGR of 5.31%. These services comprise specialized administrative and operational activities-such as site selection, patient recruitment, data management, and regulatory compliance-that pharmaceutical and biotechnology sponsors outsource to ensure the effective execution of clinical studies. The market is primarily driven by the increasing complexity of trial protocols and the urgent need to accelerate drug development timelines, which compels companies to rely on external expertise for operational efficiency. This demand is underpinned by substantial financial commitments, evidenced by the European Federation of Pharmaceutical Industries and Associations reporting that the pharmaceutical industry invested approximately €52.4 billion in research and development across Europe in 2023.

A significant challenge that could hinder market growth is the persistent difficulty in recruiting and retaining eligible trial participants. High patient dropout rates and the logistical hurdles involved in accessing diverse demographic groups frequently result in costly delays and prolonged study durations. These bottlenecks create substantial inefficiencies that strain the resources of both service providers and sponsors, effectively limiting the overall capacity of the clinical research ecosystem to deliver timely results and delaying the introduction of new medical therapies.

Market Driver

Escalating biopharmaceutical R&D expenditures serve as a fundamental catalyst for the market, necessitating the strategic outsourcing of non-core functions to specialized providers to maintain financial viability. As drug developers face increasing pressure to optimize capital allocation and mitigate the financial risks associated with clinical failures, they increasingly rely on external support for monitoring, data management, and regulatory affairs. This trend is demonstrated by massive capital injections into development pipelines; for instance, Merck & Co., Inc. reported full-year R&D expenses of $30.5 billion in their 2023 Annual Report, reflecting an intense investment strategy that sustains the demand for operational expertise within the clinical research ecosystem.

Concurrently, the rising prevalence of chronic and infectious diseases is expanding the scope of clinical research, increasing both the volume and complexity of necessary trials. This surge in disease burden compels sponsors to initiate large-scale studies requiring extensive patient recruitment, site management, and logistical coordination, particularly in oncology and immunology. According to the American Cancer Society's 'Cancer Facts & Figures 2024', it was projected that 2,001,140 new cancer cases would be diagnosed in the United States alone, signaling a critical need for robust clinical evaluation of new treatments. This medical need translates into market activity, as evidenced by the U.S. Food and Drug Administration confirming the approval of 55 novel therapeutics in 2023, a high volume that underscores the extensive support services required to navigate the regulatory pathway.

Market Challenge

The persistent struggle to recruit and retain eligible trial participants constitutes a severe bottleneck for the Global Clinical Trials Support Services Market. When patient enrollment targets are missed, the entire clinical development timeline is extended, forcing support service providers to allocate personnel and technological resources to ongoing projects for periods significantly longer than anticipated. This operational stagnation prevents Contract Research Organizations (CROs) and specialty vendors from freeing up capacity to initiate new contracts, thereby directly capping their revenue potential and slowing overall market turnover.

According to the Association of Clinical Research Professionals, in 2024, 36% of clinical research sites identified recruitment and retention as a top operational challenge impacting their study performance. Such delays disrupt the financial ecosystem of the market, as service payments are frequently tied to specific enrollment milestones. Consequently, the inability to efficiently secure participants creates a drag on the industry's capacity to scale, effectively hampering the growth of support services despite the rising global demand for clinical research.

Market Trends

The integration of Artificial Intelligence (AI) for predictive analytics and patient recruitment is fundamentally reshaping clinical trial operations by enabling more precise site selection and accelerating data processing. Service providers are increasingly deploying machine learning algorithms to mine electronic health records, identifying eligible patient populations with higher accuracy than traditional screening methods. This technological shift directly addresses the inefficiencies of manual data handling, allowing sponsors to optimize protocol feasibility and reduce trial timelines effectively. According to the Pistoia Alliance's 'Lab of the Future 2025 Global Survey', 63% of life science organizations identified AI as their primary technology investment area, signaling a decisive move toward automated, data-driven trial execution strategies to maintain operational competitiveness.

The widespread adoption of decentralized and hybrid clinical trial models represents a critical evolution in service delivery, moving study activities from physical sites to patients' homes via telemedicine and mobile healthcare support. This model not only enhances patient retention by reducing travel burdens but also serves as a primary mechanism for meeting regulatory requirements regarding participant diversity. By dismantling geographical barriers, support services can effectively reach underrepresented demographics that traditional site-based studies often exclude. According to the Tufts Center for the Study of Drug Development's 'PACT Consortium Analysis' in January 2025, decentralized trial methods increased the participation rate of Asian patients to 20.9% compared to just 14.2% in traditional trials, validating the model's efficacy in expanding population access and data representativeness.

Key Market Players

• Charles River Laboratories International, Inc.
• Wuxi Apptec
• IQVIA Inc
• Syneos Health
• Eurofins Scientific
• Ppd, Inc (Thermo Fisher Scientific Inc.)
• ICON plc
• Laboratory Corporation Of America Holdings
• Parexel International (MA) Corporation

Report Scope

In this report, the Global Clinical Trials Support Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Support Services Market, By Service

• Clinical Trial Site Management
• Patient Recruitment Management (Patient recruitment & registry services, Patient retention, Others)
• Data Management
• Administrative staff
• IRB
• Others

Clinical Trials Support Services Market, By Sponsor

• Pharmaceutical & Biopharmaceutical
• Medical Devices
• Others

Clinical Trials Support Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trials Support Services Market.

Available Customizations:

Global Clinical Trials Support Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trials Support Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Clinical Trial Site Management, Patient Recruitment Management( Patient recruitment & registry services, Patient retention, Others), Data Management, Administrative staff, IRB, Others)
  • 5.2.2. By Sponsor (Pharmaceutical & Biopharmaceutical, Medical Devices, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Clinical Trials Support Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Sponsor
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trials Support Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Sponsor
  • 6.3.2. Canada Clinical Trials Support Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Sponsor
  • 6.3.3. Mexico Clinical Trials Support Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Sponsor

7. Europe Clinical Trials Support Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Sponsor
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trials Support Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Sponsor
  • 7.3.2. France Clinical Trials Support Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Sponsor
  • 7.3.3. United Kingdom Clinical Trials Support Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Sponsor
  • 7.3.4. Italy Clinical Trials Support Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Sponsor
  • 7.3.5. Spain Clinical Trials Support Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Sponsor

8. Asia Pacific Clinical Trials Support Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Sponsor
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Trials Support Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Sponsor
  • 8.3.2. India Clinical Trials Support Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Sponsor
  • 8.3.3. Japan Clinical Trials Support Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Sponsor
  • 8.3.4. South Korea Clinical Trials Support Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Sponsor
  • 8.3.5. Australia Clinical Trials Support Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Sponsor

9. Middle East & Africa Clinical Trials Support Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Sponsor
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Trials Support Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Sponsor
  • 9.3.2. UAE Clinical Trials Support Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Sponsor
  • 9.3.3. South Africa Clinical Trials Support Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Sponsor

10. South America Clinical Trials Support Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Sponsor
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Trials Support Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Sponsor
  • 10.3.2. Colombia Clinical Trials Support Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Sponsor
  • 10.3.3. Argentina Clinical Trials Support Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Sponsor

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Trials Support Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories International, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Wuxi Apptec
• 15.3. IQVIA Inc
• 15.4. Syneos Health
• 15.5. Eurofins Scientific
• 15.6. Ppd, Inc (Thermo Fisher Scientific Inc.)
• 15.7. ICON plc
• 15.8. Laboratory Corporation Of America Holdings
• 15.9. Parexel International (MA) Corporation

16. Strategic Recommendations

17. About Us & Disclaimer